Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26093
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOpstelten, Rianne-
dc.contributor.authorSuwandi, Jessica S-
dc.contributor.authorSlot, Manon C-
dc.contributor.authorMorgana, Florencia-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorLaban, Sandra-
dc.contributor.authorNikolic, Tatjana-
dc.contributor.authorTurksma, Annelies W-
dc.contributor.authorKroeze, Anna-
dc.contributor.authorVoermans, Carlijn-
dc.contributor.authorZwaginga, Jaap-Jan-
dc.contributor.authorRoep, Bart O-
dc.contributor.authorAmsen, Derk-
dc.date2021-03-17-
dc.date.accessioned2021-03-24T21:38:58Z-
dc.date.available2021-03-24T21:38:58Z-
dc.date.issued2021-06-
dc.identifier.citationEuropean Journal of Immunology 2021; 51(6): 1377-1389en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26093-
dc.description.abstractThe Immunoglobulin superfamily protein glycoprotein A33 (GPA33) has been implicated in immune dysregulation, but little is known about its expression in the immune compartment. Here, we comprehensively determined GPA33 expression patterns on human blood leukocyte subsets, using mass and flow cytometry. We found that GPA33 was expressed on fractions of B, dendritic, natural killer and innate lymphoid cells. Most prominent expression was found in the CD4+ T cell compartment. Naïve and CXCR5+ regulatory T cells were GPA33high , and naïve conventional CD4+ T cells expressed intermediate GPA33 levels. The expression pattern of GPA33 identified functional heterogeneity within the CD4+ central memory T cell (Tcm) population. GPA33+ CD4+ Tcm cells were fully undifferentiated, bona fide Tcm cells that lack immediate effector function, whereas GPA33- Tcm cells exhibited rapid effector functions and may represent an early stage of differentiation into effector/effector memory T cells before loss of CD62L. Expression of GPA33 in conventional CD4+ T cells suggests a role in localization and/or preservation of an undifferentiated state. These results form a basis to study the function of GPA33 and show it to be a useful marker to discriminate between different cellular subsets, especially in the CD4+ T cell lineage. This article is protected by copyright. All rights reserved.en
dc.language.isoeng-
dc.subjectCD4+ T cell differentiationen
dc.subjectCyTOFen
dc.subjectantibody therapyen
dc.subjectflow cytometryen
dc.subjecthuman glycoprotein A33en
dc.titleGPA33 is expressed on multiple human blood cell types and distinguishes CD4+ central memory T cells with and without effector function.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean Journal of Immunologyen
dc.identifier.affiliationDepartment of Hematopoiesis and Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationDepartment of Diabetes Immunology, Diabetes & Metabolism Research Institute at the Beckman Research Institute, City of Hope, Duarte, CA, USAen
dc.identifier.affiliationImmunomodulation and Regenerative Cell Therapy, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlandsen
dc.identifier.affiliationDepartment of Hematopoiesis and Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationDepartment of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationImmunomodulation and Regenerative Cell Therapy, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlandsen
dc.identifier.affiliationSanquin Research, Center for Clinical Transfusion Research and Jon J van Rood Center for Clinical Transfusion Science, Leiden University Medical Center, Leiden, Netherlandsen
dc.identifier.affiliationDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Hematopoiesis and Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationImmunomodulation and Regenerative Cell Therapy, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlandsen
dc.identifier.affiliationDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.affiliationDepartment of Hematopoiesis and Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlandsen
dc.identifier.doi10.1002/eji.202048744en
dc.type.contentTexten
dc.identifier.orcid0000-0003-0596-9876en
dc.identifier.pubmedid33728639-
local.name.researcherScott, Andrew M
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Nov 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.